Recruiting
A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
I4V-MC-JAHV - ClinicalTrials.gov - NCT03773978
The reason for this study is to see if the study drug baricitinib given by mouth is safe and effective in participants with juvenile idiopathic arthritis (JIA) from 2 years to less than 18 years old.
How long will I be in the trial?
The study will last about 44 weeks and may include up to 17 visits.
Recruiting
A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
I4V-MC-JAHV - ClinicalTrials.gov - NCT03773978
The reason for this study is to see if the study drug baricitinib given by mouth is safe and effective in participants with juvenile idiopathic arthritis (JIA) from 2 years to less than 18 years old.
How long will I be in the trial?
The study will last about 44 weeks and may include up to 17 visits.
Key Requirements
Age :
2-17
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
2-17
Sex
All
Participants must
Participants must have had a diagnosis of any form of JIA, except systemic JIA, before 16 years of age and JIA must be active
Participants must have had an inadequate response to at least one conventional or biologic disease-modifying anti-rheumatic drug (DMARD)
Participants must NOT
Participants must not have systemic JIA, with or without active systemic features
Participants must not have persistent oligoarticular arthritis
Participants must not have been previously treated with a Janus kinase (JAK) inhibitor
Trial Summary
Conditions the trial is for
Systemic Juvenile Idiopathic Arthritis
What the trial is testing?
Baricitinib
Could I receive a Placebo?
yes
Enrollment Goal
197
Trial Dates
December 2018 - August 2021
Trial Phase
3
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
2-17
Sex
All
Participants must
Participants must have had a diagnosis of any form of JIA, except systemic JIA, before 16 years of age and JIA must be active
Participants must have had an inadequate response to at least one conventional or biologic disease-modifying anti-rheumatic drug (DMARD)
Participants must NOT
Participants must not have systemic JIA, with or without active systemic features
Participants must not have persistent oligoarticular arthritis
Participants must not have been previously treated with a Janus kinase (JAK) inhibitor
Trial Summary
Conditions the trial is for
Systemic Juvenile Idiopathic Arthritis
What the trial is testing?
Baricitinib
Could I receive a Placebo?
yes
Enrollment Goal
197
Trial Dates
December 2018 - August 2021
Trial Phase
3
Not the right fit? Sign up to receive updates on new Systemic Juvenile Idiopathic Arthritis trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Systemic Juvenile Idiopathic Arthritis Resources
